Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
Im 16. Jahr in Folge ehrt die Bayer Bitterfeld GmbH herausragende wissenschaftliche Leistungen am Institut für Pharmazie…
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2…
Sustainability is also a major challenge in the food and packaging industry. Plastic packaging is being replaced by orga…
Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds…
. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SA…
Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients…
Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs F…
Wissenschaftler:innen des Universitätsklinikums Hamburg-Eppendorf (UKE) veröffentlichen neueste Erkenntnisse aus klini…